The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Ganina K.K.

ООО «NPF «Materia Medica Holding»

Dugina Iu.L.

OOO "NPF Materia Medika Kholding", Moskva

Zhavbert E.S.

OOO «Materia Medica Holding», Moscow, Russia

Ertuzun I.A.

ООО «NPF «Materia Medica Holding»

pshteĭn O.I.

OOO "NPF Materia Medika Kholding", Moskva

Mukhin V.N.

Institute of Experimental Medicine, St. Petersburg, Russia

Abdurasulova I.N.

FSBSI «Institute of Experimental Medicine», Moscow

Antiamnesic effects divaza and its component model β-amyloid amnesia

Authors:

Ganina K.K., Dugina Iu.L., Zhavbert E.S., Ertuzun I.A., pshteĭn O.I., Mukhin V.N., Abdurasulova I.N.

More about the authors

Read: 3697 times


To cite this article:

Ganina KK, Dugina IuL, Zhavbert ES, Ertuzun IA, pshteĭn OI, Mukhin VN, Abdurasulova IN. Antiamnesic effects divaza and its component model β-amyloid amnesia. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(9):69‑74. (In Russ.)
https://doi.org/10.17116/jnevro20161169169-74

Recommended articles:
Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16
Cyto­kine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12
Differential diagnosis of Alzheimer’s disease and vascular cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cere­brospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53
Prospects for treating Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):54-60
Novel prospects for early diagnosis of cognitive impairment using Eye-tracking technology. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):13-20

References:

  1. Muhin VN, Klimenko VM. Mehanizmy narushenija dolgovremennoj potenciacii pri bolezni Al'cgejmera. Medicinskij akademicheskij zhurnal. 2014;14(1):42-51. (In Russ.).
  2. Muhin VN. Patogeneticheskie mehanizmy disfunkcii bazal'noj holinergicheskoj sistemy pri bolezni Al'cgejmera. Rossijskij fiziologicheskij zhurnal im. I.M. Sechenova. 2013;99(7):793-804. (In Russ.).
  3. Rosenberg PB, Nowrangi MA, Lyketsos CG. Neuropsychiatric symptoms in Alzheimer's disease: What might be associated brain circuits? Molecular aspects of medicine. 2015. doi: 10.1016/j.mam.2015.05.005
  4. Kumar A, Nisha CM, Silakari C, Sharma I, Anusha K, Gupta N, Nair P, Tripathi T, Kumar A. Current and novel therapeutic molecules and targets in Alzheimer's disease. Journal of the Formosan Medical Association. 2015. doi: 10.1016/j.jfma.2015.04.001
  5. Di Marco LY, Venneri A, Farkas E, Evans PC, Marzo A, Frangi AF. Vascular dysfunction in the pathogenesis of Alzheimer’s disease — A review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiological Disease. 2015. doi: 10.1016/j.nbd.2015.08.014
  6. Castagné V, Lemaire M, Kheyfets I, Dugina JL, Sergeeva SA, Epstein OI. Antibodies to S100 proteins have anxiolytic-like activity at ultra-low doses in the adult rat. J Pharm Pharmacol. 2008;60(3):309-316.  doi: 10.1211/jpp.60.3.0005
  7. Voronina TA, Sergeeva SA, Martyushev-Poklad AV, Dugina JL, Epstein OI. Antibodies to S-100 Protein in Anxiety-Depressive Disorders in Experimental and Clinical Conditions. Animal Models in Biological Psychiatry. Edit. A.V. Kalueff/ New York: Nova Science Publishers, 2006;8:137-152/
  8. Voronina TA, Belopol'skaja MV, Hejfec IA, Dugina JuL, Sergeeva SA, Jepshtejn OI. Izuchenie dejstvija sverhmalyh doz antitel k S-100 pri narushenii kognitivnyh funkcij, jemocional'nogo i nevrologicheskogo statusov v uslovijah jeksperimental'noj modeli bolezni Al'cgejmera. Bjulleten' jeksperimental'noj biologii i mediciny (Prilozhenie). 2009;148(8):174-176. (In Russ.).
  9. Voronina TA, Molodavkin GM, Sergeeva SA, Jepshtejn OI. GAMK-ergicheskaja sistema v realizacii anksioliticheskogo dejstvija «Proprotena»: jeksperimental'noe issledovanie. Bjulleten' jeksperimental'noj biologii i mediciny (Prilozhenie). 2003;1:37-39. (In Russ.).
  10. Voronina TA, Hejfec IA, Dugina JuL, Sergeeva JuL, Jepshtejn OI. Izuchenie jeffektivnosti preparata sverhmalyh doz antitel k S-100 v uslovijah jeksperimental'noj modeli gemorragicheskogo insul'ta. Bjulleten' jeksperimental'noj biologii i mediciny (Prilozhenie). 2009;148(8):170-173. (In Russ.).
  11. Pavlov IF. Vlijanie sverhmalyh doz antitel k antigenu S-100V na potreblenie saharozy pri obuchenii. Bjulleten' jeksperimental'noj biologii i mediciny. 2007;143(6):628-630. (In Russ.).
  12. Pankova TM, Starostina MV, Shtark MB, Jepshtejn OI. Nejroprotektornoe dejstvie sverhmalyh doz antitel k belku S100 v kul'ture nejroblastomy pri deprivacii kisloroda i gljukozy. Bjulleten' jeksperimental'noj biologii i mediciny. 2007;144(9):260-263. (In Russ.).
  13. Belous AS, Pokrovskaja TG, Pokrovskij MV, Kochkarov VI, Artjushkova EB, Korokina LV, Korokin MV. Primenenie preparata «Impaza» dlja korrekcii jendotelial'noj disfunkcii. Biomedicina. 2006;(4):82-83. (In Russ.).
  14. Tanaeva KK, Dugina JuL, Kachaeva EV, Jepshtein OI. Perspektivy primenenija preparata divaza v terapii hronicheskoj ishemii golovnogo mozga. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2014;(9):100-104. (In Russ.).
  15. GiovannelliL, CasamentiF, ScaliC, BartoliniL, PepeuG. Differentialeffectsofamyloidpeptidesbeta-(1-40) andbeta-(25-35) injections into the rat nucleus basalis. Neuroscience. 1995;66(4):781-792.  doi: 10.1016/0306-4522(94)00610-h
  16. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Sydney: Acad Press; 2005;207.
  17. Yamaguchi Y, Kawashima S. Effects of amyloid-beta-(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. Eur J Pharmacol. 2001;412(3):265-272.  doi: 10.1016/s0014-2999(01)00730-0
  18. de Lima MNM, Laranja DC, Bromberg E, Roesler R, Schrӧder N. Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats. Behavioural Brain Research. 2005;156:139-143.  doi: 10.1016/j.bbr.2004.05.016
  19. Bertaina-Anglade V, Enjuanes E, Morillon D, Drieu la Rochelle C. The object recognition task in rats and mice: A simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity. J Pharmacol Toxicol Methods. 2006;4:99-105.  doi: 10.1016/j.vascn.2006.04.001
  20. Epstein OI, Beregovoy NA, Sorokina NS, Starostina MV, Shtark MB, Gainutdinov KhL, Gainutdinova TKh, Muhamedshina DI. Membrane and synaptic effects of anti-S-100 are prevented by the same antibodies in low concentrations. FrontBiosci. 2003;8:79-84.  doi: 10.2741/1025
  21. Jepshtejn OI, Beregovoj NA, Sorokina NS, Starostina MV, Shtark MB. vlijanie razlichnyh razvedenij potencirovannyh antitel k mozgospecificheskomu belku S-100 na dinamiku posttetanicheskoj potenciacii v perezhivajushhih srezah gippokampa. Bjulleten' jeksperimental'noj biologii i mediciny. 1999;127(3):317-320. (In Russ.).
  22. Jepshtejn OI, Gajnutdinov HL, Shtark MB. Vlijanie gomeopaticheskih doz antitel k antigenu S-100 na jelektricheskie harakteristiki nejronal'nyh membran. Bjulleten' jeksperimental'noj biologii i mediciny. 1999;127(4):466-467. (In Russ.).
  23. Hejfec IA, Dugina JuL, Voronina TA, Molodavkin GM, Martjushev-Poklad AV, Sergeeva SA, Jepshtejn OI. Uchastie serotoninergicheskoj sistemy v mehanizme dejstvija antitel k belku S-100 v sverhmalyh dozah. Bjulleten' jeksperimental'noj biologii i mediciny. 2007;143(5):535-537. (In Russ.).
  24. Hejfec IA, Molodavkin GM, Voronina TA, Dugina JuL, Sergeeva SA, Jepshtejn OI. Uchastie GAMK-V sistemy v mehanizme dejstvija antitel k belku S-100 v sverhmalyh dozah. Bjulleten' jeksperimental'noj biologii i mediciny. 2008;145(5):552-554.(In Russ.).

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.